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Background: Rapid (“warm”) autopsies of patients with advanced metastatic cancer provide important insight into
the natural history, pathobiology and histomorphology of disease in treatment-resistant tumors. Plasmacytoid
urothelial carcinoma (PUC) is a rare variant of urothelial carcinoma characterized by neoplastic cells morphologically
resembling plasma cells. PUC is typically aggressive, high-stage at presentation, and associated with poor outcomes.
Recurrence is common in PUC, with the majority of recurrences occurring in the peritoneum.
Case presentation: Here, we report rapid autopsy findings from a patient with recurrent PUC. The patient had
persistent pain after cystoprostatectomy, although initial post-operative imaging showed no evidence of disease.
Imaging obtained shortly before his death showed only subtle growth along vascular tissue planes; however,
extensive disease was seen on autopsy. Plasmacytoid tumor cells formed sheets involving many serosal surfaces.
Molecular interrogation confirmed a mutation in CDH1 exon 12 leading to early truncation of the CDH1 protein in
the tumor cells.
Conclusions: The sheet-like growth pattern of PUC makes early phases of disease spread much more difficult to
capture on cross-sectional imaging. Alternative forms of surveillance may be required for detection of recurrent
PUC, and providers may need to treat based on symptoms and clinical suspicion.
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Rapid (“warm”) autopsies, those performed within
approximately 3 h after death, of end-stage cancer
patients help us to understand the clinical and patho-
logic aspects of therapy-resistant disease. The goal of
these autopsies is to not only establish the extent of clin-
ical disease in the patient, but to also collect tissue from
the primary tumor and metastases for molecular interro-
gation and comparison. Results of molecular assays
performed on these tissue samples contribute to our un-
derstanding of disease progression [1]. Through genetic
analysis of the patient’s primary tumor and metastases,© The Author(s). 2019 Open Access This artic
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evolution including metastatic potential and treatment
refractoriness is studied [2]. The majority of rapid autop-
sies previously reported in the literature by our group
have been for primary prostatic adenocarcinoma, with
one case report of metastatic renal cell carcinoma from
a patient with a germline fumarate hydratase mutation
[3–9]. Other institutions have reported rapid autopsies
of breast and pancreatic primary tumors [10, 11]. A
series of 10 rapid autopsies performed for urothelial car-
cinoma, including two plasmacytoid urothelial carcin-
omas has been presented in abstract form by Lam et al.,
at the American Society of Clinical Oncology meeting
[12].To the best of our knowledge no dedicated case of a
plasmacytoid urothelial carcinoma rapid autopsy has
been so far described in the literature.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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of the genitourinary tract [13]. Studies from The Cancer
Genome Atlas (TCGA) project have demonstrated po-
tential therapeutic targets in 69% of tumors [14]. Chro-
matin regulatory genes are also more frequently mutated
in urothelial carcinoma than in other common cancer
types, suggesting a possible therapeutic role for histone
deacetylase inhibitors [14, 15]. The four mutation/
focal copy number clusters were characterized by
TP53 and RB1 mutations, SOX4/E2F3 amplification,
mutations in chromatin-modifying genes, and FGFR3,
KDM6A, and STAG2 mutations [15]. TCGA studies
have demonstrated 5 distinct subtypes of muscle-
invasive bladder cancer based on mRNA expression
clustering: (1) luminal-papillary subtype (FGFR3 mu-
tation, fusion with TACC3 and/or amplification, active
sonic hedgehog signaling), (2) luminal-infiltrated sub-
type (high expression of epithelial-mesenchymal tran-
sition and myofibroblast markers, medium expression
of PD-L1 and CTLA4), (3) luminal subtype (high ex-
pression of luminal markers, KRT20, and SNX31), (4)
basal-squamous subtype (squamous differentiation,
basal keratin expression, high expression of PD-L1
and CTLA4), and (5) neuronal subtype (expression of
neuroendocrine and neuronal genes, and high cell-
cycle signature) [15]. Most of these molecular sub-
types have potential therapeutic implications.
The plasmacytoid variant of urothelial carcinoma
(PUC) was first described in 1991 and is a rare histologic
variant of UCa [16–18]. PUC is characterized by cells
that morphologically resemble plasma cells with eccen-
tric nuclei and eosinophilic cytoplasm arranged in
sheets, cords or nests that may account the entire tumor
morphology in such cases; classically, there is absent to
minimal associated stromal reaction [19]. PUC is com-
monly locally advanced at the time of presentation, ag-
gressive and tends to extensively involve the bladder
wall, frequently extending into the perivesicular soft
tissue and serosal surfaces with a high risk of local re-
currence, metastatic disease and cancer-related death
[20–22]. The rate of positive surgical margins in patients
with PUC at the time of cystectomy has been reported
to be 5 times greater than in cases of pure UCa due to
the infiltration of PUC into adjacent soft tissues [23, 24].
In one single institution retrospective review, patients
with PUC were more likely to receive adjuvant chemo-
therapy than patients with conventional UCa, given the
aggressive high stage and aggressive nature of PUC [23].
However, no difference in survival has been seen in
these patients who receive neoadjuvant chemotherapy
compared to initial surgery [20]. The most common site
of disease recurrence is the peritoneum [19]. Involve-
ment of the perivesicular, perirectal and periureteral soft
tissues is common [20–25].A few genomic studies characterizing PUC have re-
ported all cases to be highly aneuploid and polysomic
[22]. A previous study by some of our co-authors dem-
onstrated pathogenic CDH1 mutations in the majority of
PUC [26]. Deletions of chromosome 9p21 have been re-
ported to play an important role and TP53 mutations
are present in a minority of PUC [22, 27]. FGFR3 muta-
tions have been detected in approximately 60% of cases
[27]. In a recent study of 69 cases of PUC, three mor-
phologic subtypes (classic, desmoplastic, and pleo-
morphic) were identified, and the desmoplastic group
was found to have shortest survival (10 months) [27].
Here we report a rapid autopsy in a patient with ad-
vanced, treatment refractory plasmacytoid urothelial car-
cinoma, focusing on extent of metastatic disease, clinical
and pathologic phenotype, molecular underpinnings and
immunohistochemical profile.
Materials and methods
Enrollment in our rapid autopsy program known as
Michigan Legacy Tissue Program (MLTP) was secured,
and consent for autopsy by the patient’s spouse was con-
firmed posthumously prior to performance of the aut-
opsy at Michigan Medicine. The rapid autopsy protocol
has been described previously [1, 6] and was followed
during this autopsy. The entire gross dissection was
performed simultaneously by the attending genitourinary
pathologist (R.M.) and pathology residents (C.T.S. and
S.L.S.). Tissues procured at the time of autopsy were
placed in O.C.T. medium (Sakura Finetek USA, Torrance,
CA) or formalin for frozen or permanent histologic
sections, respectively. Hematoxylin and eosin (H&E),
TWORT tissue gram stain, Grocott’s methenamine
sliver stain and Ziehl-Neelsen were performed by the
Department of Pathology at Michigan Medicine using
routine laboratory methods. Immunohistochemistry by
the Department of Pathology at Michigan Medicine
was performed using a BenchMark ULTRA automated
stainer and the ultraView Universal DAB Detection
Kit (Ventana Medical Systems, Oro Valley, AZ). The
following primary antibodies were used: GATA-3
(pre-dilute; Cell Marque, Rocklin, CA); CD138 (1:100,
Cell Marque); CK7 (1:200; Cell Marque); CK20 (1:
200; Cell Marque); CK903 (1:50, Dako, Santa Clara,
CA); pancytokeratin (AE1/AE3/Cam5.2; 1:200; Chemicon/
Becton Dickinson, Franklin Lakes, NJ); p53 (predilute;
Ventana); PAX-8 (predilute; Cell Marque); E-cadherin
(predilute; Ventana); CDX-2 (predilute; Ventana); p63
(predilute; Ventana); NKX3.1 (1:25, BioCare Medical,
Pacheco, CA); PAX-2 (predilute, CellMarque); PSA (predi-
lute, Ventana); CD10 (predilute, Ventana).
Genomic DNA was isolated from the tumor and adja-
cent normal tissue from the index case using the
QIAamp DNA FFPE tissue kit (Cat. No./ID: 56404)
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Using 50 nanograms of genomic DNA from normal and
tumor samples as templated, PCR reactions (HotStarTaq
DNA Polymerase - Cat No./ID: 203203) were performed
(38 cycles, annealing temp. 60 °C) to amplify the 14 cod-
ing exonic regions of the CDH1 gene (Primer sequences;
Additional file 1: Table S1). 5′ end of the forward
primers also contain M13 forward sequence to enable
Sanger sequencing. The PCR products were first ana-
lyzed in an agarose gel to confirm the amplicon size.
Subsequently, the PCR products were treated with 2 μl
of ExoSAP-IT (Affymetrix P/N: 78201) for every 5 μl of
PCR product and incubated first at 37 °C for 15 min,
followed by 80 °C for 15 min for inactivation. Finally, the
samples were diluted and submitted for Sanger sequen-
cing (University of Michigan, DNA sequencing Core).
The sequencing chromatograms assembled and analyzed
by Sequencer 5.2 tool from Genecodes. CDH1 Ref seq
Accession number NM_004360 was used as a reference
in the analysis.
Results
Clinical history and sequence of events
The decedent was a 65-year-old Caucasian male with a
past medical history of hypertension, environmental al-
lergies and arthritis. His family history was significant
for cancer of unknown type in his maternal grandfather,
breast cancer in his mother and lung cancer in his
father. Nine months prior to death the patient presented
to an outside hospital emergency room with abdominal
pain. Subsequent work-up included computed tomog-
raphy (CT) of the abdomen and pelvis, which showed a
thickened left lateral wall and dome of the urinary blad-
der. A biopsy at the site of CT abnormality showed
muscle invasive poorly differentiated carcinoma with sig-
net ring features, favoring urothelial primary, while a
transurethral resection of bladder tumor (TURBT)
showed muscle invasive high-grade UCa. The TURBT
slides were not reviewed at Michigan Medicine. At that
time of the biopsy a positron emission tomography
(PET) scan showed no evidence of nodal disease.
The patient underwent neoadjuvant chemotherapy
(3 cycles of dose-dense Methotrexate, Vinblastine,
Doxorubicin and Cisplatin). PET scan after neoadju-
vant chemotherapy showed persistent thickened blad-
der wall and mild metabolic activity. A subsequent
cystoprostatectomy and bilateral inguinal lymph node
dissection with ileal conduit formation was performed
5 months prior to death. The cystoprostatectomy ma-
terial, which was reviewed for pathologic assessment
at Michigan Medicine, showed high grade carcinoma,
7 cm per gross report, with extensive signet ring/plas-
macytoid differentiation. The resection specimen dem-
onstrated gross invasion into the perivesicular softtissue, with a positive right perivesicular soft tissue
margin. Five of six lymph nodes were positive for
metastatic disease. At the time of cystoprostatectomy
prostatic adenocarcinoma, Gleason score 3 + 4 = 7,
Grade Group 2, with established extraprostatic exten-
sion on the right side was also identified. Given the
discovery of the prostatic adenocarcinoma and lack of
a surface urothelial neoplasm, immunohistochemical
stains were performed on the tumor arising in the
bladder, which was p63 positive (patchy) and prostate
specific antigen (PSA) negative. Given these findings
along with the previous history, the primary bladder
disease was considered to be urothelial in origin.
Approximately 1 month after cystoprostatectomy
the patient presented at Michigan Medicine to estab-
lish care. There was a clinical trial evaluating whether
adjuvant atezolizumab was beneficial for high-risk lo-
calized disease (NCT02450331), but our patient was
not eligible since his tumor was not predominantly
conventional transitional cell carcinoma. When it was
determined that he had relapsed, his Eastern Cooperative
Oncology Group (ECOG) performance status had de-
clined too much to allow therapy to be attempted
and close clinical follow-up and pain management
was recommended. The patient’s serum PSA was un-
detectable. CT of the abdomen and pelvis at 1.5
months post-operative was negative for relapse. Re-
peat imaging (now including chest also) at 3 months
post-operative showed an area concerning for disease
in the left hemi-pelvis, but no evidence of distant
metastatic disease. He developed leg swelling during a
long trip and was diagnosed at an outside institution
with a deep vein thrombosis (DVT) and given a dose
of enoxaparin and started on rivaroxaban. Nine days
after treatment for DVT, the patient developed short-
ness of breath and presented at Michigan Medicine
where he was diagnosed with pulmonary emboli of the
left lower lobe and right middle lobe and a subacute
DVT in the right lower extremity. The patient
remained hospitalized at Michigan Medicine for 8
days, during which a PET scan showed disease pro-
gression in the pelvis with peritoneal carcinomatosis,
right diaphragmatic and anterior chest wall nodules.
Seventeen days prior to death the patient was admit-
ted with worsening abdominal and scrotal swelling.
CT abdomen and pelvis showed interval progression
of disease and more extensive carcinomatosis. During
his 2-day hospitalization he developed shortness of
breath requiring a respiratory rapid response. He was
transitioned to comfort care and was discharged with
home hospice and comfort measures 15 days prior to
death. After death the patient was transported to
Michigan Medicine for participation in the rapid aut-
opsy program.
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The left lower lobe of the lung was adherent to the dia-
phragm in a thickened, white plaque. There were mul-
tiple punctate white lesions (up to 0.2 cm) on the pleural
surface of the posterior aspect of the lower lobe of the
right lung, right pleural cavity and diaphragm. The peri-
toneal/serosal surfaces were diffusely thickened by tan to
white tumor (Fig. 1a, b and Fig. 2a). Microscopically, all
sites of tumor showed sheets of single high-grade carcin-
oma cells with plasmacytoid morphology. The cells were
large and round with eccentric nuclei and eosinophilic
cytoplasm. A subset of cells had a signet ring-like
morphology with large cytoplasmic vacuoles. Individual
tumor cells were noted to infiltrate the skeletal muscle
of the right abdominal wall (Fig. 2b). White-tan firm
nodules and plaques diffusely involved the mesenteryFig. 1 Plasmacytoid Urothelial Carcinoma in the Abdomen (in Situ). The di
before evisceration by arrow) and the peritoneal/serosal surface was diffuse
by arrow)and omentum. The ileum (including 5 × 4 × 3 cm area of
ileal conduit leading up to the stoma) (Fig. 2c), trans-
verse colon and rectum were focally encased by white-
tan tumor with gross invasion of the tumor into the
muscular walls of the ileum and transverse colon. Micro-
scopic sections confirmed that carcinoma involved the
submucosa of the ileum (Fig. 2d), transverse colon and
rectum. Multiple pale tan plaques involved the gallblad-
der serosa. The soft tissue around the appendix showed
diffuse thickening, and a 2 cm tan nodule was identified
adjacent to the appendix (Fig. 2e). Microscopically, car-
cinoma involved the muscularis of the appendix (Fig. 2f).
Diffuse lymphadenopathy (up to 3 cm) in the paraeso-
phageal, paraaortic and paravertebral regions was noted.
The bilateral lungs showed extensive vascular space in-
volvement with metastatic carcinoma and a parenchymalaphragm was diffusely thickened in a white plaque of tumor (a, shown
ly thickened in a white plaque of tumor (b, shown after evisceration
Fig. 2 Plasmacytoid Urothelial Carcinoma in the Abdomen. The abdominal wall and peritoneum were grossly thickened with a white plaque (a).
The skeletal muscle of the right abdominal wall was diffusely infiltrated by plasmacytoid tumor cells (b) [H&E 200x; inset 400x]. The lower
gastrointestinal tract was diffusely involved with tumor encasing the ileum (c) with involvement of the submucosa (d) [H&E 200x] and the
appendix (e) with tumor extending into the muscularis (f) [H&E 200x]. Tumor was present throughout the abdomen in the omentum, gallbladder,
colon and rectum. Extra-abdominal metastases were present in the lungs, pleura, diaphragm and lymph nodes (not pictured)
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left diaphragm. A 3 cm vegetation was present on the
pulmonic valve; microscopically, this was composed of
fibrin and karyorrhectic debris without tumor. In the
area of the pancreas there was extensive tumor; no de-
finitive normal pancreatic tissue could be identified, sug-
gesting the pancreas was completely replaced by the
neoplastic process. The spleen, liver, heart, bilateral kid-
neys, brain, thyroid and bone marrow were grossly not
involved by tumor. The urinary bladder and prostate
were surgically absent.
Ancillary studies
Prior to coming to Michigan Medicine, microsatellite in-
stability (MSI) testing and PD-L1 staining were per-
formed on formalin-fixed, paraffin-embedded (FFPE)
bladder tissue. The tumor was microsatellite stable, and
the PD-L1 22C3 tumor proportion score was 0%. Al-
though MSI testing is not routinely done, PD-L1 stain-
ing can be useful for selection of appropriate first linetherapy in the metastatic setting. With our patient’s
rapid clinical decline precluding any systemic therapy,
expanded next generation sequencing was not consid-
ered to be appropriate for his clinical management.
Tumor cells with the plasmacytoid/signet ring-like
morphology demonstrated strong expression of GATA-3
(Fig. 3a), pancytokeratin, CK7 (Fig. 3b) and CK20 (Fig.
3c), patchy expression of CD138, CK903, and p53, and
focal expression of PAX-8. The tumor cells demon-
strated loss of E-cadherin (Fig. 3d), with negative CDX-
2, p63, NKX3.1, PAX-2, and PSA expression.
Molecular analysis performed on the index tumor
demonstrated a deleterious mutation in CDH1 exon 12
leading to early truncation of the CDH1 protein in the
index tumor sample which was absent from the adjacent
benign tissue (Fig. 4).
Electron microscopic evaluation of a representative
section of tumor showed nuclei pushed aside by intracel-
lular vacuoles with microvilli lining the inner surface
(Fig. 5 a, c). Given this finding reminiscent of
Fig. 3 Immunohistochemical Profile of Plasmacytoid Urothelial Carcinoma in the Right Abdominal Wall. Hematoxylin and Eosin demonstrates
carcinoma in sheets splaying the skeletal muscle (a). The neoplastic cells are diffusely positive for GATA-3 (b), CK20 (c), and CK7 (d). A subset of
neoplastic cells is positive for CD 138 (e). E-cadherin is negative (f). Additional immunohistochemical stains show the tumor cells are diffusely
positive for pancytokeratin, patchy expression of CK903, and p53, and focal expression of PAX-8 and negative for CDX-2, p63, NKX3.1, PAX-2
and PSA
Simon et al. Diagnostic Pathology          (2019) 14:113 Page 6 of 10microvillous inclusion disease, a CD10 immunohisto-
chemical stain was performed and showed apical/lu-
minal staining (H&E Fig. 5b, CD10 Fig. 5d) .
Discussion
Here we describe a rapid autopsy case of advanced
metastatic plasmacytoid urothelial carcinoma. To our
knowledge, this is the first case report of a rapid autopsy
performed for a patient with plasmacytoid urothelial car-
cinoma. Our patient presented with abdominal pain and
was subsequently diagnosed with invasive high-grade
UCa with plasmacytoid features. His treatment-resistant
high-grade UCa demonstrated extensive peritoneal car-
cinomatosis and distant metastases involving multiple
areas of the gastrointestinal tract, the biliary system,
lungs, pleural surface, diaphragm, paraesophageal,
paraaortic and paravertebral lymph nodes. The tumor
cells displayed the classic plasmacytoid appearance with
eccentric nuclei and eosinophilic cytoplasm, with a
remarkable absence of any associated stromal reaction.Ancillary studies demonstrated expression of expected
urothelial markers (GATA-3, pancytokeratin, CK7,
CK20), patchy expression of plasma cell markers
(CD138) and loss of expression for E-cadherin protein.
PUC is an aggressive variant of UCa. Similar to other
reports of PUC, our patient had advanced (stage pT3b)
and lymph node metastases at the time of diagnosis [28].
The plasmacytoid component of PUC varies in previous
reports from 30 to 100% with the majority of cases dem-
onstrating pure plasmacytoid morphology [19, 28]. Our
case is an example of the more common pure plasmacy-
toid morphology with no identifiable conventional high-
grade urothelial carcinoma component. Given the possi-
bility of other malignancies which may manifest a similar
morphology, it is important to rule out other tumors
with plasmacytoid morphologies including plasmacy-
toma, signet ring cell adenocarcinoma and metastatic
carcinomas from other primary sites, especially the
breast and stomach [28–31]. The previously described
immunophenotype of PUC reported in literature
Fig. 4 (See legend on next page.)
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Fig. 4 Deleterious mutation in CDH1 exon-12 in the index tumor sample. Chromatograms indicate the mutant allele present in the tumor sample
(red arrows), both in the forward and reverse strand sequencing. The tumor specific mutation in exon-12; C1828T_Q610Stop gain, leads to early
truncation of the CDH1 protein. The wild type allele (blue arrows) in the corresponding nucleotide position, detected in the adjacent normal
sample from this index case, both in the forward and reverse strands are shown alongside for comparison (a). A nearby single nucleotide
polymorphism (SNP) position in Exon 13 T/C2076T A692A_SNP_position (rs1801552) shows loss of heterozygosity of CDH1 loci in the tumor (b).
Location of the deleterious stop gain mutation (red lollipop) observed in the index tumor (Sample name in red) and various missense mutations
(green lollipops; of unknown significance) observed among the TCGA Bladder Urothelial Carcinomas (6/121 samples)- is represented in the CDH1
pfam protein domain structure schematic diagram using the Mutation Mapper tool (www.cbioportal.org) (c)
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AE1/AE3, frequent expression of the plasma cell marker
CD138, and absence of expression of E-cadherin in the
plasmacytoid morphology [19, 27, 28, 32, 33]. Coupled
with the clinical presentation of disease and pattern of
spread, immunohistochemistry may play an important
role in determining the primary site of disease. The
immunophenotype of our case was similar to the cases
previously described, with diffuse expression of urothe-
lial markers, patchy CD138 expression, and loss of E-
cadherin expression.
The presence of intracytoplasmic lumina with project-
ing microvilli on electron microscopy has been previ-
ously described, as has the presence of intracytoplasmic
bundles of tonofilaments [34]. Additionally, the electron
microscopic features of our case are similar to those de-
scribed in microvillus inclusion disease, an autosomal
condition causing congenital diarrhea and failure to
thrive [35] that results from mutations in the MY05B,Fig. 5 Electron microscopy analysis and CD10 immunostain of plasmacyto
representative section of tumor demonstrated nuclei pushed aside by intra
Hematoxylin and eosin of the tumor (b) and a CD10 immunostain showing
microvillous inclusion disease (d)which encodes a cytoskeleton motor protein [36]. Micro-
villus inclusion disease is almost always fatal within the
first 2–3 years of life [37], and there is no known in-
creased risk of malignancy in these patients. Microvillus
inclusion disease has a characteristic apical cytoplasmic
staining pattern in the enterocytes with CD10 immuno-
stain [38]. Given the similarity of ultrastructural findings
between our case and reported cases of microvillus in-
clusion disease, a CD10 stain was performed and showed
a similar pattern to microvillus inclusion disease. Given
these similarities, further studies may be warranted to
examine the possibility of a genetic relationship between
microvillus inclusion disease and PUC.
Similar to other cases that have been described, our
patient had recurrence with extensive peritoneal carcin-
omatosis and involvement of the perirectal soft tissue. In
its earliest form, this PUC carcinomatosis manifests in a
“sheet” like growth pattern rather than “nodular”- simi-
lar to its molecular counterpart, hereditary diffuseid urothelial carcinoma. Electron microscopy was performed on a
cellular vacuoles with microvilli lining the inner surface (a,c),
an apical cytoplasmic staining pattern, similar to those reported in
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spread much more difficult to capture on cross-sectional
imaging, making clinical surveillance for relapse harder
and potentially requiring a different staging approach
(i.e. peritoneal washings and/or PET). Unfortunately, this
patient suffered secondary to this challenge. His pain
after surgery never improved (likely from residual dis-
ease affecting pelvic nerves), while 6-week post-operative
imaging was negative for recurrence. His 3-month post-
operative imaging only revealed subtle growth along vas-
cular tissue planes on coronal slices adjacent to the left
common iliac and left internal iliac vessels, yet shortly
after his autopsy revealed extensive involvement of the
gastrointestinal tract, submucosa of the rectum, and
muscular invasion of the appendix, transverse colon and
ileum, as well as extensive disease involving the pleura,
lung parenchyma, diaphragm and gallbladder. This type
of encasing growth has also been reported in the duode-
num, with involvement of the submucosa [33].
For this variant histology, the treating provider must
maintain vigilance and understand the inherent limita-
tions in diagnosing relapse of this disease. Alternative
forms of surveillance (e.g. PET) may potentially be re-
quired, and providers may need to treat based on symp-
toms and clinical suspicion. Given the advanced stage
and aggressive behavior of PUC, prognosis is poor. Our
patient died of disease 9 months after his initial diagno-
sis, which is similar to other reports [19, 20, 28]. Finally,
our patient’s tumor demonstrated a deleterious mutation
in CDH1 exon 12 leading to early truncation of the
CDH1 protein, similar to the findings of our previous
study [26]. Patients with hereditary diffuse gastric cancer
(germline CDH1 mutation) undergo prophylactic gas-
trectomy due to the challenge in early diagnosis of this
type of carcinoma [39]. Standard imaging and intraop-
erative frozen sections often underestimate disease bur-
den for both diffuse gastric cancer and plasmacytoid
urothelial carcinoma. PUC was excluded from the
original studies showing benefit of neoadjuvant chemo-
therapy for these reasons, as well as its rarity. Although
multiple retrospective studies have attempted to
evaluate the benefit of chemotherapy for PUC, there is
information about a limited number of patients and
retrospective studies have inherent biases. Metastatic
conventional urothelial carcinoma can be treated with
immunotherapy either post-platinum chemotherapy or
as a first-line in cisplatin-ineligible patients with tumors
showing high PD-L1 staining. Again, PUC was excluded
from the clinical trials, and to our knowledge, there are
no specific reports about the responsiveness of PUC to
PD1 or PD-L1 blockade. Because cisplatin-based
chemotherapy has significant risks and the benefit is
unclear, early cystectomy is our recommended ap-
proach for PUC management.Conclusions
In summary, we present rapid autopsy findings from a
unique patient with extensively metastatic treatment
resistant PUC. As we continue to expand our rapid autopsy
program (MLTP) we will aim to include more patients with
this rare variant of UCa and other genitourinary malignan-
cies allowing for opportunities to further understand the
tumorigenesis and malignant spread, locally aggressive ver-
sus distant metastases and valuable clinical correlations
with molecular annotations.
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